CD14 and cancer: • Reverses monocyte deactivation in sepsis by inducing HLA-DR expression • Utility in cancer patients remains to be determined. • May also promote the development of CD14+HLA-DRlo/neg monocytes, dependent on dosing, timing, and other mechanisms.